Metabolic reprogramming of amino acids dictates tumor susceptibility to ferroptosis
Ferroptosis and Oxidative Stress · 2025
DOI: 10.70401/fos.2026.0023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ferroptosis and Oxidative Stress, 2025. Verfasst von Guangyao Shan und 4 weiteren Autor:innen. Die Arbeit nennt 128 Literaturangaben.
Abstract (Originalsprache)
Metabolic reprogramming fundamentally drives cancer progression, with aberrant amino acid metabolism serving as a critical nexus for maintaining redox homeostasis and dictating cell fate. Ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation, is closely related to intracellular amino acid metabolic networks. Here, we systematically delineate how key amino acids function as multi-dimensional regulatory nodes that orchestrate tumor cell susceptibility to ferroptosis. We provide a focused analysis of the context-dependent mechanisms through which these metabolic pathways rewire cellular redox capacity, modulate central anti-ferroptotic defense nodes (e.g., GPX4), and reshape the tumor microenvironment. Finally, we highlight the profound metabolic plasticity and spatiotemporal heterogeneity of these networks, exposing the intrinsic vulnerabilities within the amino acid-ferroptosis axis that drive drug resistance and tumor evolution.
Zitieren
APA
Shan, G., Bian, Y., Ren, S., Bi, G., & Zhan, C. (2025). Metabolic reprogramming of amino acids dictates tumor susceptibility to ferroptosis. Ferroptosis and Oxidative Stress. https://doi.org/10.70401/fos.2026.0023
Vancouver
Shan G, Bian Y, Ren S, Bi G, Zhan C. Metabolic reprogramming of amino acids dictates tumor susceptibility to ferroptosis. Ferroptosis and Oxidative Stress. 2025. doi:10.70401/fos.2026.0023
BibTeX
@article{Shan2025,
author = {Shan, Guangyao and Bian, Yunyi and Ren, Shencheng and Bi, Guoshu and Zhan, Cheng},
title = {Metabolic reprogramming of amino acids dictates tumor susceptibility to ferroptosis},
journal = {Ferroptosis and Oxidative Stress},
year = {2025},
doi = {10.70401/fos.2026.0023}
}
EUVIMED